Monitoring RA Disease Activity

Calprotectin vs Acute-Phase Reactants to Discriminate RA, PsA Activity

Calprotectin discriminate disease activity in RA patients receiving tumor necrosis factor inhibitors more effectively than acute-phase reactants.
rheumatologyadvisor.com

Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis

from a longitudinal study of patients with established rheumatoid arthritis
Calprotectin (S100A8/A9 or MRP8/14) and S100A12 (leukocyte-derived proteins), interleukin 6 (IL-6) and vascular endothelial growth factor (VEGF) are markers of inflammation and angiogenesis. Ultrasound (US) is sensitive for detection of greyscale synovitis and power Doppler (PD) vascularization. The…
arthritis-research.biomedcentral.com

Serum calprotectin level discriminated between clinical remission and low disease activity better than other acute phase reactants like ESR and CRP, correlating with composite disease activity measures and ultrasound grey scale and power Doppler gradings.


Long noncoding RNA expression profile in fibroblast-like synoviocytes from patients with rheumatoid arthritis

Long noncoding RNAs (lncRNAs) have recently…
arthritis-research.biomedcentral.com

Requiring synovial biopsy, flow cytometry to isolate the fibroblast-like synoviocytes, and doing quantitative PCR to measure the long non–coding RNA expression, this test is so not making it to clinical practice anytime soon.


Chronic peripheral inflammation in diseases such as rheumatoid arthritis leads to alterations in central pain processing and consequently to mood disorders resulting from sensitization within the central nervous system and enhanced vulnerability of the …
ncbi.nlm.nih.gov

“…amelioration of pain and improvement of personal subjective feeling set in soon after the start of TNF neutralization, long before inflammation decline becomes identifiable using common clinical tests.”

Association of brain functional magnetic resonance activity with response to tumor necrosis factor inhibition in rheumatoid arthritis

onlinelibrary.wiley.com

“…brain activity decreased within 3 days after TNFi exposure in the responders, preceding clinical responses (day 7) and responses observed on the anatomic hand MRI (day 28).”